EYPT Q4 2022 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M-8.8% YoY

Gross Profit

$7M67.6% margin

Operating Income

-$44M-415.2% margin

Net Income

-$43M-412.5% margin

EPS (Diluted)

$-1.72

QoQ Revenue Growth

+5.2%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$180M

Total Liabilities

$84M

Stockholders' Equity

$96M

Cash & Equivalents

$96M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$12M	-8.8%
Gross Profit	$7M	$9M	-16.3%
Operating Income	-$44M	-$18M	-142.3%
Net Income	-$43M	-$19M	-123.6%

Revenue Segments

Y U T I Q Product

$9M86%

D E X Y C U Product

$833,0008%

Royalty

$474,0005%

License And Collaboration Agreement

$202,0002%